



Cotter, J., Granger, K., Backx, R., Hobbs, M., Looi, C. Y., & Barnett, J. H. (2018). Social cognitive dysfunction as a clinical marker: A systematic review of meta-analyses across 30 clinical conditions. *Neuroscience and Biobehavioral Reviews*, 84, 92-99.  
<https://doi.org/10.1016/j.neubiorev.2017.11.014>,  
<https://doi.org/10.1016/j.neubiorev.2017.11.014>

Publisher's PDF, also known as Version of record

License (if available):  
CC BY

Link to published version (if available):  
[10.1016/j.neubiorev.2017.11.014](https://doi.org/10.1016/j.neubiorev.2017.11.014)  
[10.1016/j.neubiorev.2017.11.014](https://doi.org/10.1016/j.neubiorev.2017.11.014)

[Link to publication record in Explore Bristol Research](#)  
PDF-document

## University of Bristol - Explore Bristol Research

### General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available:  
<http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/>



## Review article

## Social cognitive dysfunction as a clinical marker: A systematic review of meta-analyses across 30 clinical conditions



Jack Cotter<sup>a,\*</sup>, Kiri Granger<sup>a</sup>, Rosa Backx<sup>a</sup>, Matthew Hobbs<sup>a</sup>, Chung Yen Looi<sup>a,b</sup>,  
Jennifer H. Barnett<sup>a,c</sup>

<sup>a</sup> Cambridge Cognition, Cambridge, UK

<sup>b</sup> School of Experimental Psychology, University of Bristol, Bristol, UK

<sup>c</sup> Department of Psychiatry, University of Cambridge, Cambridge, UK

## ARTICLE INFO

## Keywords:

Emotion

Theory of mind

Social cognition

Transdiagnostic

Systematic review

Meta-analysis

## ABSTRACT

Social cognition includes a range of cognitive processes that help individuals to understand how others think and feel. There is emerging evidence that social cognitive deficits may represent a transdiagnostic issue, potentially serving as a marker of neurological abnormality. We performed an electronic database search in order to identify published, peer-reviewed meta-analyses that compared facial emotion recognition or theory of mind task performance between individuals meeting clinical criteria for a psychiatric, neurological or developmental condition against healthy controls. We identified 31 meta-analyses eligible for inclusion that examined performance across relevant tasks among 30 different clinical populations. The results suggest that social cognitive deficits appear to be a core cognitive phenotype of many clinical conditions. Across the clinical groups, deficits in social cognitive domains were broadly similar in magnitude to those previously reported for more established aspects of cognition, such as memory and executive function. There is a need to clarify the ‘real world’ impact of these deficits, and to develop effective transdiagnostic interventions for those individuals that are adversely affected.

## 1. Introduction

Social cognition refers to the ‘mental operations that underlie social interactions’ and includes a range of cognitive processes that help individuals to understand how others think and feel (Frith, 2008; Green et al., 2008). The most heavily researched aspects of social cognition are emotion recognition and theory of mind (ToM); two partially overlapping but distinct cognitive domains (Mitchell and Phillips, 2015). Emotion recognition refers to an individual’s ability to identify and discriminate between the basic emotional states of others, typically based on their facial or vocal expressions. Theory of mind refers to the ability to infer more complex mental states, including the intentions, dispositions, and beliefs of others, and is thought to comprise distinguishable but overlapping cognitive and affective components (Green et al., 2015; Poletti et al., 2012). Collectively these drive interpersonal skills such as empathy, and are thought to be important for fluid communication and social interaction.

The neural basis of social cognitive processing is complex, involving a range of cortical and subcortical regions and connective pathways (Van Overwalle, 2009). This ‘social brain’ network varies depending on task demands, but is broadly thought to include limbic regions (such as

the amygdala), the prefrontal cortex and temporoparietal junction, as well as the anterior cingulate and insular cortex (Forbes and Grafman, 2010; Lavin et al., 2013; Lindquist et al., 2012; Molenberghs et al., 2016). Many of these regions are adversely affected in people with neurological or psychiatric conditions (Batista et al., 2017a, 2017b; Cusi et al., 2012; Patriquin et al., 2016; Seeley et al., 2009), suggesting social cognitive dysfunction may be common across these populations.

Pioneering early work in this field focused on the central role of ToM impairments as a hallmark feature of autism spectrum disorders (Baron-Cohen et al., 1985; Happé and Frith, 1996). Subsequently, deficits in both emotion recognition and ToM have been identified as core cognitive deficits in schizophrenia (Savla et al., 2013; Kohler et al., 2010), and have been reported to be among the strongest predictors of impaired social functioning in this population (Fett et al., 2011; Galderisi et al., 2014; Green, 2016). There is also preliminary evidence that deficits in social cognitive processes may contribute to deterioration in psychosocial functioning in other clinical groups (Aydemir et al., 2013; Phillips et al., 2011; Trevisan and Birmingham, 2016). More recently, some aspects of emotion recognition have also been proposed to play a causal role in the onset and maintenance of a range of mental health conditions (Penton-Voak et al., 2017). As a result, investigation

\* Corresponding author at: Cambridge Cognition, Tunbridge Court, Bottisham, Cambridge, CB25 9TU, UK.  
E-mail address: [jack.cotter@camcog.com](mailto:jack.cotter@camcog.com) (J. Cotter).

<https://doi.org/10.1016/j.neubiorev.2017.11.014>

Received 15 June 2017; Received in revised form 4 October 2017; Accepted 21 November 2017

Available online 24 November 2017

0149-7634/ © 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

of social cognitive dysfunction has become an emerging area of interest across a range of developmental, psychiatric and neurological disorders (Bora and Pantelis, 2016; Cotter et al., 2016; Plana et al., 2014).

Despite recent calls emphasising its importance (Henry et al., 2016), social cognitive assessment has been largely overlooked clinically to date. This could have the potential to serve as a marker of neural deterioration and disease progression, particularly for neurodegenerative conditions, as well as treatment response. There has also been little consideration of these deficits as a transdiagnostic issue. Social cognitive deficits potentially represent an under recognised domain of impairment across disorders, with both functional and clinical relevance. In this review, we sought to collate existing meta-analytic data on social cognitive performance among individuals with a range of clinical conditions.

## 2. Method

This review was conducted in line with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (Moher et al., 2009).

### 2.1. Study inclusion criteria

Eligible articles were meta-analyses published in peer-reviewed journals that examined the difference in performance on facial emotion recognition or ToM tasks between individuals with a clinically diagnosed psychiatric, neurological or developmental condition and healthy controls. Facial emotion recognition effect size estimates were required to have been derived from tasks in which participants had to identify, label or match images of faces consisting of all or any combination of the six basic emotions (happiness, sadness, anger, fear, surprise or disgust) (Ekman and Friesen, 1976). Where possible, a ‘total’ score was used, comprising performance across multiple emotions. ToM or ‘mentalizing’ tasks required the identification or interpretation of more complex mental states and/or beliefs (such as lies, jokes, sarcasm or faux pas).

Standardised mean difference effect size estimates (Cohen’s *d* or Hedges’ *g*) must have been derived from two or more independent studies in order for the meta-analysis to be included. Where data was reported for different states of a given condition (e.g. remitted/acute symptoms), we included the overall ‘pooled’ estimates from across those states when available. Where there were multiple publications for a given medical condition that met our inclusion criteria, we included the most recently published paper. Meta-analyses of interventions were ineligible. No language restrictions were placed on studies for inclusion.

### 2.2. Search strategy

On 1st May 2017, we conducted an electronic database search of Ovid MEDLINE, PsycINFO, Embase and the Cochrane Database of Systematic Reviews (from inception) using the following keyword search terms: “social cogniti\*” or “theory of mind” or “mentalizing” or “emotion” and “meta-analysis”. In addition; a search of Google Scholar was conducted and the reference lists of retrieved articles were also reviewed to identify any additional relevant publications. An additional eligible meta-analysis that was published following the formal search date was also later identified and included.

### 2.3. Study selection and data extraction

Three of the authors (J.C., R.B. and M.H.) independently screened articles for eligibility. A standardised data extraction spreadsheet was used for all eligible studies to record: (1) study characteristics (authors, year of publication, clinical condition(s) examined); (2) social cognitive domains assessed (facial emotion recognition and/or ToM); (3) sample characteristics (the number of studies and the sample sizes for the

clinical and control groups included for each of the summary estimates); (4) social cognitive performance in the clinical relative to control group (effect size, effect size metric and associated 95% confidence intervals).

Effect sizes generated using either Cohen’s *d* or Hedges’ *g* were included. These represent the difference between the clinical and control group means, divided by the pooled standard deviation and weighted for sample size. Hedges’ *g* includes an additional correction for small sample size bias, but is broadly comparable to Cohen’s *d* (Lakens, 2013). Effect sizes generated using either approach are typically interpreted as representing small ( $\leq 0.2$ ), medium (0.5), or large ( $\geq 0.8$ ) group differences based on these methods (Cohen, 1988). Scores were re-coded where necessary so that negative effect size estimates always reflected poorer performance in the clinical group relative to controls. Where data was reported from both fixed and random effects models, we included the results from the random effects analyses. These models provide more conservative estimates by accounting for observed heterogeneity. Where reported, we also recorded the degree of heterogeneity within effect size estimates ( $I^2$  statistic), as well as any tests that were performed to detect evidence of potential publication bias (Egger’s test, Begg’s test and/or the Fail-safe *N*). Effect size estimates were classified as having a ‘low risk’ or ‘possible risk’ of publication bias based on the results of these analyses.

## 3. Results

The study selection process is summarised in Fig. 1. We identified 31 meta-analyses eligible for inclusion that examined performance on facial emotion recognition (24 papers) and/or ToM tasks (24 papers) among 30 different clinical populations relative to controls (Table 1). Across clinical conditions, the facial emotion recognition and ToM effect size estimates each collectively included data acquired from around 20,000 clinical and control participants. Though the effect sizes are not directly comparable across clinical conditions (due to methodological differences between studies and in meta-analytic procedures), they demonstrate consistent and statistically significant deficits in facial emotion recognition and ToM across almost all of the clinical groups included in this review (Figs. 2 and 3). These also provide an indication of the magnitude of these difficulties. Within specific conditions, the severity of deficits in facial emotion recognition and ToM task performance were broadly comparable with one another, suggesting patients with particular disorders have similar levels of difficulty across each of these social cognitive domains. Among individuals with neurological or developmental disorders, deficits across both task types were in the medium-to-large range ( $-0.41$  to  $-1.81$ ). Individuals with psychiatric disorders exhibited wider variation in the severity of these deficits, potentially due to greater variability in disease state and severity. Perhaps unsurprisingly, the greatest impairments were observed in patients with neurodegenerative disorders, though large deficits were also observed in people with psychotic disorders.


Heterogeneity was evident in the effect size estimates and ranged from low to high. There was a possible risk of publication bias associated with 7 of the 34 effect size estimates that included tests for publication bias, suggesting overall that these results provide a robust indication that social cognitive deficits are common across many of the included clinical populations.

## 4. Discussion

### 4.1. Overview of findings

In summary, we identified significant deficits among individuals with a wide range of clinical conditions in their ability to identify emotions from facial expressions and to successfully complete ToM tasks, compared to healthy controls. Though these results do not provide directly comparable estimates between clinical conditions, they

Fig. 1. PRISMA flow diagram.



provide a robust indication that social cognitive deficits appear to be a core cognitive phenotype of many developmental, neurological and psychiatric disorders.

#### 4.2. Social cognition as a clinical marker

Across many conditions, deficits in social cognitive domains were broadly similar in magnitude to those previously reported on more established aspects of cognition, such as memory, processing speed and executive function (e.g. Beeldman et al., 2016; Demetriou et al., 2017; Fioravanti et al., 2012; Prakash et al., 2008). The distinction between neurocognitive and social cognitive processing remains an area of ongoing investigation. Though social cognitive deficits are likely to be exacerbated as a secondary deficit to more general cognitive impairments (for example, on tasks requiring rapid processing or a memory component), there is evidence that these are dissociable cognitive constructs. For example, neuroimaging studies suggest that these domains rely on different (though partially overlapping) neural systems, while analysis of performance on social and neurocognitive tasks demonstrate that these also form different factors (Bertoux et al., 2016; Mehta et al., 2013; Van Overwalle, 2009). Studies have also indicated that social cognitive dysfunction is exhibited by patients with otherwise intact cognitive and perceptual performance (Cotter et al., 2016; Fanning et al., 2012; Lagravinese et al., 2017). Given that these neurocognitive deficits are a target for therapeutic intervention in many disorders, the magnitude of social cognitive deficits should also be considered clinically meaningful.

Social cognitive impairment has been posited as a potential marker for autism and schizophrenia (Derntl and Habel, 2011). However, the findings of this review suggest it may serve as a general biomarker indicative of neurological abnormality across a range of clinical conditions and warrants further attention. The results from this review suggest that social cognitive measures should be integrated into large-

scale, longitudinal projects (alongside existing neurocognitive measures) using repeated assessments in order to examine their potential to serve as longitudinal predictors of clinical and functional outcomes.

There is emerging evidence that social cognitive performance may serve as a useful screening tool among individuals with neurodegenerative conditions. The presence of social cognitive deficits in pre-manifest Huntington's disease have been reported to indicate a significantly higher risk of developing motor symptoms in the following 5 years (Bora et al., 2016b). Social cognitive screening also has the potential to help improve early diagnosis between different forms of cortical dementias (Bertoux and Hornberger, 2015). Individuals with behavioural-variant frontotemporal dementia exhibited significantly poorer performance across both facial emotion recognition and ToM tasks compared to those with Alzheimer's disease, despite worse Mini-Mental State Examination performance in the Alzheimer's group (Bora et al., 2016a, 2015a). Effect size differences across these measures were much larger than those previously reported across more traditional neurocognitive tasks (Hutchinson and Mathias, 2007). This suggests that social cognitive measures may be useful for identifying which individuals are in the early stages of, or at risk of developing behavioural-variant frontotemporal dementia compared to Alzheimer's disease, particularly among patients with mild cognitive impairment.

As well as being a potential marker for disease onset, social cognitive assessment also appears to offer the potential to examine disease progression. There was evidence that social cognitive deficits were evident even among individuals in the early stages of a number of conditions, with only mild levels of disease severity (Bora, 2017; Bora et al., 2015b; Cotter et al., 2016; van Donkersgoed et al., 2015), but also that they were more severe in those individuals with neurological conditions with a longer disease duration (Bora et al., 2016b, 2015a), and those with psychiatric disorders experiencing an exacerbation in symptom severity (Bora et al., 2016c; Bora and Berk, 2016; Bora and Köse, 2016).

**Table 1**  
Overview of included meta-analyses.

Condition	Reference	Domains assessed	Studies included	Sample	n	Effect size (95% CI)	Effect size metric	Heterogeneity ( $I^2$ )	Publication bias
<b>Psychiatric disorders</b>									
At-risk mental state	van Donkersgoed et al. (2015)	FER	10	Clinical	444	−0.48 (−0.69, −0.27)	Cohen's d	N/R	N/R
		ToM	7	Clinical	375	−0.44 (−0.68, −0.19)	Cohen's d	N/R	N/R
First-episode psychosis	Barkl et al. (2014)	FER	11	Clinical	348	−0.88 (−1.42, −0.32)	Cohen's d	N/R	N/R
		ToM	8	Clinical	378	−1.00 (−1.18, −0.81)	Cohen's d	0%	Low risk
Schizophrenia	Bora and Pantelis (2013)	FER	53	Clinical	285	−0.91 (−0.97, −0.84)	Cohen's d	N/R	Possible risk
		ToM	50	Clinical	3822	−0.96 (−1.09, −0.83)	Hedges' g	66.50%	Possible risk
Bipolar disorder	Kohler et al. (2011)	FER	31	Clinical	1760	−0.46 (−0.63, −0.29)	Cohen's d	N/R	N/R
		ToM	34	Clinical	N/R	−0.63 (−0.74, −0.52)	Cohen's d	36.50%	Possible risk
Major depressive disorder	Dalili et al. (2015)	FER	22	Clinical	1214	−0.16 (−0.25, −0.07)	Hedges' g	0%	Possible risk
		ToM	18	Clinical	843	−0.58 (−0.84, −0.33)	Cohen's d	74.80%	Low risk
Borderline personality disorder	Daros et al. (2013)	FER	10	Clinical	529	−0.45 (−0.80, −0.09)	Cohen's d	N/R	Low risk
		ToM	5	Clinical	266	−0.06 (−0.26, 0.13)	Cohen's d	N/R	N/R
Generalised anxiety disorder	Richman and Unoka (2015)	FER	2	Clinical	224	−0.12 (N/R)	Cohen's d	N/R	N/R
		ToM	2	Clinical	58	−0.16 (N/R)	Cohen's d	N/R	N/R
Obsessive-compulsive disorder	Plana et al. (2014)	FER	12	Clinical	48	−0.30 (N/R)	Cohen's d	N/R	N/R
		ToM	2	Clinical	313	−0.30 (N/R)	Cohen's d	N/R	N/R
Panic disorder	Plana et al. (2014)	FER	2	Clinical	55	−0.25 (N/R)	Cohen's d	N/R	N/R
		ToM	2	Clinical	55	−0.25 (N/R)	Cohen's d	N/R	N/R
Social phobia	Plana et al. (2014)	FER	10	Clinical	73	−0.20 (N/R)	Cohen's d	N/R	N/R
		ToM	10	Clinical	217	−0.20 (N/R)	Cohen's d	N/R	N/R
Post-traumatic stress disorder	Plana et al. (2014)	FER	4	Clinical	239	−1.60 (N/R)	Cohen's d	N/R	N/R
		ToM	4	Clinical	68	−1.60 (N/R)	Cohen's d	N/R	N/R
Anorexia Nervosa	Caglar-Nazali et al. (2014)	FER	5	Clinical	63	−0.32 (−0.55, −0.09)	Cohen's d	N/R	Low risk
		ToM	14	Clinical	185	−0.59 (−0.81, −0.37)	Cohen's d	N/R	N/R
Bulimia Nervosa	Bora and Köse (2016)	FER	2	Clinical	441	0.01 (−0.33, 0.36)	Cohen's d	N/R	Low risk
		ToM	8	Clinical	51	−0.34 (−0.58, −0.09)	Cohen's d	45.31%	N/R
Alcohol use disorder	Bora and Zorlu (2017)	FER	12	Clinical	227	−0.65 (−0.89, −0.42)	Cohen's d	60.18%	Low risk
		ToM	12	Clinical	352	−0.58 (−0.81, −0.36)	Cohen's d	44.55%	Low risk
Substance use disorder (non-alcohol)	Castellano et al. (2015)	FER	10	Clinical	298	−0.65 (−0.93, −0.37)	Cohen's d	72.50%	Low risk
<b>Neurological disorders</b>									
Alzheimer's disease	Bora et al. (2015a)	ToM	20	Clinical	402	−1.15 (−1.52, −0.79)	Cohen's d	N/R	Low risk
Amyotrophic lateral sclerosis	Bora (2017)	FER	5	Clinical	421	−0.69 (−0.97, −0.42)	Cohen's d	0%	Low risk
		ToM	11	Clinical	152	−0.65 (−0.84, −0.47)	Cohen's d	21%	Possible risk
Behavioural variant frontotemporal dementia	Bora et al. (2016a)	FER	13	Clinical	339	−1.81 (−2.28, −1.35)	Cohen's d	80.7%	Low risk
		ToM	20	Clinical	237	−1.79 (−2.18, −1.40)	Cohen's d	N/R	Low risk
Frontal lobe epilepsy	Stewart et al. (2016)	ToM	3	Clinical	334	−1.03 (−1.33, −0.72)	Hedges' g	N/R	Low risk
Idiopathic generalised epilepsy	Stewart et al. (2016)	ToM	2	Clinical	125	−0.59 (−0.87, −0.31)	Hedges' g	N/R	Low risk
Temporal lobe epilepsy	Bora and Meletti (2016)	FER	16	Clinical	62	−0.87 (−1.05, −0.69)	Cohen's d	46.55%	Low risk
		ToM	11	Clinical	580	−0.86 (−1.07, −0.64)	Cohen's d	49.95%	Low risk

(continued on next page)

Table 1 (continued)

Condition	Reference	Domains assessed	Studies included	Sample	n	Effect size (95% CI)	Effect size metric	Heterogeneity ( $I^2$ )	Publication bias
Huntington's disease	Bora et al. (2016b)	FER <sup>a</sup>	18	Clinical	413	−1.33 (−1.52, −1.14)	Cohen's d	N/R	Possible risk
		ToM	12	Controls	446	−1.72 (−2.09, −1.35)	Cohen's d	70%	Low risk
Mild cognitive impairment	Bora and Yener (2017)	FER	13	Clinical	370	−0.58 (−0.73, −0.43)	Cohen's d	0%	Low risk
		ToM	6	Controls	434	−0.63 (−0.91, −0.35)	Cohen's d	34%	Low risk
Multiple sclerosis	Cotter et al. (2016)	FER	13	Clinical	473	−0.64 (−0.81, −0.47)	Hedges' g	36%	Low risk
		ToM	12	Controls	423	−0.71 (−0.88, −0.55)	Hedges' g	23%	Low risk
Parkinson's disease	Gray and Tickle-Degnen (2010) Bora et al. (2015b)	FER	28	Clinical	1110	−0.41 (−0.64, −0.19)	Hedges' g	N/R	Low risk
		ToM	18	Controls	487	−0.83 (−1.09, −0.57)	Cohen's d	N/R	Low risk
Traumatic brain injury	Babbage et al. (2011)	FER	13	Clinical	296	−1.11 (−1.25, −0.97)	Hedges' g	N/R	Low risk
<b>Developmental disorders</b>									
Attention deficit hyperactivity disorder	Bora and Pantelis (2016)	FER	25	Clinical	1021	−0.44 (−0.59, −0.30)	Cohen's d	N/R	Low risk
		ToM	24	Controls	764	−0.45 (−0.62, −0.29)	Cohen's d	N/R	Low risk
Autism spectrum disorder	Chung et al. (2014)	ToM	11	Clinical	264	−0.81 (−1.14, −0.48)	Hedges' g	N/R	Possible risk
Intellectual disability	Yirmiya et al. (1998)	ToM	17	Controls	243	−0.45 (−0.61, −0.29)	Cohen's d	N/R	N/R
Specific language impairment (children)	Nilsson and de López (2016)	ToM	17	Clinical	329	−0.98 (−1.23, −0.74)	Cohen's d	55.23%	Low risk

**Abbreviations:** CI: Confidence Interval; FER: Facial emotion recognition; N/R: Not reported; ToM: Theory of Mind.

<sup>a</sup> Negative emotions subscale score; comprising total score for anger, disgust, sadness and fear facial affect recognition tasks only.

#### 4.3. Strengths and limitations

This is the first review to our knowledge to examine social cognition across such a broad range of clinical disorders. As a result, we concentrated on facial emotion recognition and ToM, which have been the overwhelming focus of research in this field to date. Currently, ToM tasks are typically grouped together, though these include a relatively heterogeneous array of measures, requiring participants to make

inferences regarding sarcasm, hints, faux pas and/or complex affective states (for example see Baron-Cohen et al., 2001; Corcoran et al., 1995; Gregory et al., 2002). In future, differentiation of tasks assessing cognitive and affective components of ToM may provide greater sensitivity to domain-specific impairments. Similarly, though 'global' scores indicated a deficit among clinical groups in the identification of facial emotions, there was variation in the emotion-specific patterns of deficits among the different clinical conditions. A greater understanding of




Fig. 2. Facial emotion recognition effect size estimates and corresponding 95% confidence intervals across clinical conditions relative to healthy controls.

\*95% CI data not available.

\*\*Negative emotions subscale score, comprising total score for anger, disgust, sadness and fear facial affect recognition tasks only.

**Abbreviations:** ADHD: Attention deficit hyperactivity disorder; ALS: Amyotrophic lateral sclerosis; ARMS: At-risk mental state; BD: Bipolar disorder; BPD: Borderline personality disorder; BVFTD: Behavioural variant frontotemporal dementia; FEP: First-episode psychosis; GAD: Generalised anxiety disorder; MCI: Mild cognitive impairment; MDD: Major depressive disorder; MS: Multiple sclerosis; OCD: Obsessive-compulsive disorder; PD: Panic disorder; PTSD: Post-traumatic stress disorder; SP: Social phobia; SUD: Substance use disorder (non-alcohol); TBI: Traumatic brain injury.






Fig. 3. Theory of mind effect size estimates and corresponding 95% confidence intervals across clinical conditions relative to healthy controls.

\*95% CI data not available

**Abbreviations:** ADHD: Attention deficit hyperactivity disorder; ALS: Amyotrophic lateral sclerosis; ARMS: At-risk mental state; ASD: Autism spectrum disorder; BD: Bipolar disorder; BPD: Borderline personality disorder; BVFTD: Behavioural variant frontotemporal dementia; FEP: First-episode psychosis; IG: Idiopathic generalised epilepsy; MCI: Mild cognitive impairment; MDD: Major depressive disorder; MS: Multiple sclerosis; OCD: Obsessive-compulsive disorder.

these condition-specific emotion recognition profiles could provide further insight into underlying disease pathology. For example, the recognition of fear and sadness has been reported to be strongly associated with the integrity of medial temporal lobe structures, whereas disgust is more closely associated with the insular cortex, though there is evidence of considerable overlap across emotions (Adolphs, 2002). There are also other aspects of social cognition which have received comparatively little attention. Vocal tasks, for example, are potentially more sensitive than faces for identifying emotion recognition deficits in Parkinson's disease (Gray and Tickle-Degnen, 2010), and can also be used to assess emotion recognition among individuals with visual impairments. Bodily affect recognition is also an emerging area of interest across disorders, providing an additional approach for social cognitive assessment (Cecchetto et al., 2014; Vaskinn et al., 2016).

Though many of the original research studies matched the clinical and control groups for various demographic characteristics (such as age, sex and level of education), this was inconsistently reported across the included meta-analyses and may have influenced their results. Variation in the clinical and demographic samples of the included studies, as well as the range of social cognitive assessments that were used, are likely to have contributed to the statistical heterogeneity that was observed among many of the effect size estimates. Comorbidities are also common across many of these disorders and could be considered as a potential confounder. For example, depression is common among people with psychiatric and neurological diagnoses (Fusar-Poli et al., 2014; Siegert and Abernethy, 2005; Ulfvebrand et al., 2015), and may have influenced emotional processing. However, a number of studies included in the meta-analyses explicitly excluded individuals with major depressive disorder or else reported no association between the severity of depressive symptoms with social cognitive task performance, suggesting social cognitive deficits were not secondary to depressive comorbidity (e.g. Cotter et al., 2016; Daros et al., 2013; Gray and Tickle-Degnen, 2010). The impact of other common comorbid neuropsychiatric symptoms such as apathy and anxiety on social cognitive performance is less well understood, though the results presented in this review suggest the latter is unlikely to be a major causal factor for social cognitive decline.

The majority of the meta-analyses included in this review included a large number of studies and participants, providing robust effect size estimates. However, given this is an emerging field, several of the epilepsy, PTSD, anxiety and eating disorder estimates were based on a limited pool of original research studies and should be interpreted with

caution. Similarly, tests for evidence of publication bias associated with each of the effect size estimates indicated a low risk of publication bias across the majority of the meta-analyses included in this review. However, some of the meta-analyses included a relatively small number of studies (< 10 for each estimate), and are therefore likely to be underpowered to detect evidence of potential publication bias (Higgins and Green, 2011). Many of the meta-analyses also performed meta-regression analyses to examine potential clinical, cognitive and demographic moderators of these effect sizes. However, these meta-regression analyses would have been underpowered to detect anything but very large study-level effects since, in many cases, they would include only aggregate data from a relatively small number of studies. We therefore did not include the results of these moderator analyses in the current review.

#### 4.4. Future opportunities in social cognitive research

Impairments in social and occupational functioning and reduced quality of life are common across a wide range of psychiatric, developmental and neurological disorders. There is emerging evidence that social cognitive dysfunction may contribute to such difficulties (Aydemir et al., 2013; Bishop-Fitzpatrick et al., 2017; Cotter et al., 2017; Fett et al., 2011; Phillips et al., 2011; Trevisan and Birmingham, 2016). In addition to ongoing psychiatric or neurological symptoms, misperception of others emotional or mental states coupled with difficulties in empathising during social situations may play a causal role in the breakdown of interpersonal relationships (Couture et al., 2006). Though these links would benefit from further (particularly longitudinal) investigation, social cognitive dysfunction does represent a potentially modifiable risk factor for these difficulties (Penton-Voak et al., 2017). Assessment and treatment of social cognitive dysfunction may also offer wider treatment benefits. For example, recent evidence suggests that cognitive training aimed at treating facial emotion recognition biases exhibited by individuals with low mood can also help to alleviate their depressive symptoms (Iacoviello et al., 2014; Penton-Voak et al., 2012).

Despite the evidence that social cognitive dysfunction is common among individuals with a range of medical conditions, targeted treatments for these deficits remain in their relative infancy. The most widely researched pharmacological agent for the treatment of social cognitive impairment has been oxytocin, a neuropeptide hormone thought to play a key role in social behaviours (Meyer-Lindenberg et al.,

2011). Despite some promising trials conducted in patients with psychotic, affective and autism spectrum disorders (Mercedes Perez-Rodriguez et al., 2015; Preti et al., 2014), its benefits appear inconsistent across studies and methodologically problematic (Bradley and Woolley, 2017; Leppanen et al., 2017). At present, more effective approaches have involved the use of social cognitive remediation, though these also appear to offer only modest benefits (García-Casal et al., 2017; Kurtz et al., 2016).

An important limitation in this area is the poor or unknown psychometric properties of many social cognitive tests, though efforts are currently underway to establish how these measures compare (Pinkham et al., 2016). Improved characterisation and operationalization of social cognition and other ‘hot’ cognitive processes are necessary to facilitate and advance treatment efforts. There are currently a wide range of measures in use (Henry et al., 2015), which also makes direct comparisons between studies difficult. In an effort to combat this, test batteries such as EMOTICOM are currently under development, providing comprehensive computerised assessments for social cognitive and cognitive-affective processes that can be used across both healthy individuals and clinical populations (Bland et al., 2016).

#### 4.5. Conclusion

Social cognitive deficits appear to be a core cognitive phenotype of many developmental, neurological and psychiatric disorders. There is a need to raise awareness of the importance of these difficulties among clinicians, researchers and patients alongside the more established aspects of cognition that may be negatively affected, such as attention and memory. Future studies should seek to address the ‘real world’ implications of these deficits and to develop effective transdiagnostic interventions for those individuals that are adversely affected.

#### Role of the funding source

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

#### Declaration of interest

The authors are employees of Cambridge Cognition. CYL is supported through a Knowledge Transfer Partnership (KTP) grant funded by Innovate UK, the Economic and Social Research Council and Cambridge Cognition.

#### References

- Adolphs, R., 2002. Neural systems for recognizing emotion. *Curr. Opin. Neurobiol.* 12 (2), 169–177.
- Aydemir, O., Akkaya, C., Uykur, B., Erol, A., 2013. Effect of facial emotion recognition on subjective psychosocial functioning in bipolar patients. *Acta Psychiatr. Scand.* 127 (5), 412–413.
- Babbage, D.R., Yim, J., Zupan, B., Neumann, D., Tomita, M.R., Willer, B., 2011. Meta-analysis of facial affect recognition difficulties after traumatic brain injury. *Neuropsychology* 25 (3), 277–285.
- Barkl, S.J., Lah, S., Harris, A.W., Williams, L.M., 2014. Facial emotion identification in early-onset and first-episode psychosis: a systematic review with meta-analysis. *Schizophr. Res.* 159 (1), 62–69.
- Baron-Cohen, S., Leslie, A.M., Frith, U., 1985. Does the autistic child have a theory of mind? *Cognition* 21 (1), 37–46.
- Baron-Cohen, S., Wheelwright, S., Hill, J., Raste, Y., Plumb, I., 2001. The Reading the Mind in the Eyes Test revised version: a study with normal adults, and adults with Asperger syndrome or high-functioning autism. *J. Child Psychol. Psychiatry* 42 (2), 241–251.
- Batista, S., d’Almeida, O.C., Afonso, A., Freitas, S., Macário, C., Sousa, L., Castelo-Branco, M., Santana, I., Cunha, L., 2017a. Impairment of social cognition in multiple sclerosis: amygdala atrophy is the main predictor. *Mult. Scler.* 23 (10), 1358–1366.
- Batista, S., Alves, C., d’Almeida, O.C., Afonso, A., Félix-Morais, R., Pereira, J., Macário, C., Sousa, L., Castelo-Branco, M., Santana, I., Cunha, L., 2017b. Disconnection as a mechanism for social cognition impairment in multiple sclerosis. *Neurology* 89 (1), 38–45.
- Beeldman, E., Raaphorst, J., Klein Twennaar, M., de Visser, M., Schmand, B.A., de Haan, R.J., 2016. The cognitive profile of ALS: a systematic review and meta-analysis update. *J. Neurol. Neurosurg. Psychiatry* 87 (6), 611–619.
- Bertoux, M., Hornberger, M., 2015. ‘Try to see it my way’: which theory of mind tests best distinguish bvFTD and AD? *J. Neurol. Neurosurg. Psychiatry* 86 (7), 706.
- Bertoux, M., O’Callaghan, C., Dubois, B., Hornberger, M., 2016. In two minds: executive functioning versus theory of mind in behavioural variant frontotemporal dementia. *J. Neurol. Neurosurg. Psychiatry* 87 (3), 231–234.
- Bishop-Fitzpatrick, L., Mazefsky, C.A., Eack, S.M., Minshew, N.J., 2017. Correlates of social functioning in autism spectrum disorder: the role of social cognition. *Res. Autism Spectr. Disord.* 35, 25–34.
- Bland, A.R., Roiser, J.P., Mehta, M.A., Schei, T., Boland, H., Campbell-Meiklejohn, D.K., Emsley, R.A., Munafo, M.R., Penton-Voak, I.S., Seara-Cardoso, A., Viding, E., Voon, V., Sahakian, B.J., Robbins, T.W., Elliott, R., 2016. EMOTICOM: a neuropsychological test battery to evaluate emotion, motivation, impulsivity, and social cognition. *Front. Behav. Neurosci.* 10, 25.
- Bora, E., Berk, M., 2016. Theory of mind in major depressive disorder: a meta-analysis. *J. Affect. Disord.* 191, 49–55.
- Bora, E., Köse, S., 2016. Meta-analysis of theory of mind in anorexia nervosa and bulimia nervosa: a specific impairment of cognitive perspective taking in anorexia nervosa? *Int. J. Eat. Disord.* 49 (8), 739–749.
- Bora, E., Meletti, S., 2016. Social cognition in temporal lobe epilepsy: a systematic review and meta-analysis. *Epilepsy Behav.* 60, 50–57.
- Bora, E., Pantelis, C., 2013. Theory of mind impairments in first-episode psychosis, individuals at ultra-high risk for psychosis and in first-degree relatives of schizophrenia: systematic review and meta-analysis. *Schizophr. Res.* 144 (1–3), 31–36.
- Bora, E., Pantelis, C., 2016. Meta-analysis of social cognition in attention-deficit/hyperactivity disorder (ADHD): comparison with healthy controls and autistic spectrum disorder. *Psychol. Med.* 46 (4), 699–716.
- Bora, E., Yener, G.G., 2017. Meta-analysis of social cognition in mild cognitive impairment. *J. Geriatr. Psychiatry Neurol.* 30 (4), 206–213.
- Bora, E., Zorlu, N., 2017. Social cognition in alcohol use disorder: a meta-analysis. *Addiction* 112 (1), 40–48.
- Bora, E., Walterfang, M., Velakoulis, D., 2015a. Theory of mind in behavioural-variant frontotemporal dementia and Alzheimer’s disease: a meta-analysis. *J. Neurol. Neurosurg. Psychiatry* 86 (7), 714–719.
- Bora, E., Walterfang, M., Velakoulis, D., 2015b. Theory of mind in Parkinson’s disease: a meta-analysis. *Behav. Brain Res.* 292, 515–520.
- Bora, E., Velakoulis, D., Walterfang, M., 2016a. Meta-analysis of facial emotion recognition in behavioral variant frontotemporal dementia: comparison with Alzheimer disease and healthy controls. *J. Geriatr. Psychiatry Neurol.* 29 (4), 205–211.
- Bora, E., Velakoulis, D., Walterfang, M., 2016b. Social cognition in Huntington’s disease: a meta-analysis. *Behav. Brain Res.* 297, 131–140.
- Bora, E., Bartholomeusz, C., Pantelis, C., 2016c. Meta-analysis of theory of mind (ToM) impairment in bipolar disorder. *Psychol. Med.* 46 (2), 253–264.
- Bora, E., 2017. Meta-analysis of social cognition in amyotrophic lateral sclerosis. *Cortex* 88, 1–7.
- Bradley, E.R., Woolley, J.D., 2017. Oxytocin effects in schizophrenia: reconciling mixed findings and moving forward. *Neurosci. Biobehav. Rev.* 80, 36–56.
- Caglar-Nazali, H.P., Corfield, F., Cardi, V., Ambwani, S., Leppanen, J., Olabintan, O., Deriziotis, S., Hadjimichalis, A., Scognamiglio, P., Eshkevari, E., Micali, N., Treasure, J., 2014. A systematic review and meta-analysis of ‘Systems for Social Processes’ in eating disorders. *Neurosci. Biobehav. Rev.* 42, 55–92.
- Castellano, F., Bartoli, F., Crocamo, C., Gamba, G., Tremolada, M., Santambrogio, J., Clerici, M., Carrà, G., 2015. Facial emotion recognition in alcohol and substance use disorders: a meta-analysis. *Neurosci. Biobehav. Rev.* 59, 147–154.
- Cecchetto, C., Aiello, M., D’Amico, D., Cutuli, D., Cargnelutti, D., Eleopra, R., Rumiati, R.I., 2014. Facial and bodily emotion recognition in multiple sclerosis: the role of alexithymia and other characteristics of the disease. *J. Int. Neuropsychol. Soc.* 20 (10), 1004–1014.
- Chung, Y.S., Barch, D., Strube, M., 2014. A meta-analysis of mentalizing impairments in adults with schizophrenia and autism spectrum disorder. *Schizophr. Bull.* 40 (3), 602–616.
- Cohen, J., 1988. *Statistical Power Analysis for the Behavioral Sciences*. Lawrence Erlbaum Associates, USA.
- Corcoran, R., Mercer, G., Frith, C.D., 1995. Schizophrenia, symptomatology and social inference: investigating theory of mind in people with schizophrenia. *Schizophr. Res.* 17 (1), 5–13.
- Cotter, J., Firth, J., Enzinger, C., Kontopantelis, E., Yung, A.R., Elliott, R., Drake, R.J., 2016. Social cognition in multiple sclerosis: a systematic review and meta-analysis. *Neurology* 87 (16), 1727–1736.
- Cotter, J., Bartholomeusz, C., Papas, A., Allott, K., Nelson, B., Yung, A.R., Thompson, A., 2017. Examining the association between social cognition and functioning in individuals at ultra-high risk for psychosis. *Aust. N. Z. J. Psychiatry* 51 (1), 83–92.
- Couture, S.M., Penn, D.L., Roberts, D.L., 2006. The functional significance of social cognition in schizophrenia: a review. *Schizophr. Bull.* 32 (Suppl. 1), S44–63.
- Cusi, A.M., Nazarov, A., Holshausen, K., Macqueen, G.M., McKinnon, M.C., 2012. Systematic review of the neural basis of social cognition in patients with mood disorders. *J. Psychiatry Neurosci.* 37 (3), 154–169.
- Dalili, M.N., Penton-Voak, I.S., Harmer, C.J., Munafo, M.R., 2015. Meta-analysis of emotion recognition deficits in major depressive disorder. *Psychol. Med.* 45 (6), 1135–1144.
- Daros, A.R., Zakzanis, K.K., Ruocco, A.C., 2013. Facial emotion recognition in borderline personality disorder. *Psychol. Med.* 43 (9), 1953–1963.
- Demetriou, E.A., Lampit, A., Quintana, D.S., Naismith, S.L., Song, Y.J.C., Pye, J.E., Hickie, I., Guastella, A.J., 2017. Autism spectrum disorders: a meta-analysis of executive function. *Mol. Psychiatry*. <http://dx.doi.org/10.1038/mp.2017.75>. in press.



- Derntl, B., Habel, U., 2011. Deficits in social cognition: a marker for psychiatric disorders? *Eur. Arch. Psychiatry Clin. Neurosci.* 261 (Suppl. 2), S145–9.
- Ekman, P., Friesen, W.V., 1976. *Pictures of Facial Affect*. Consulting Psychologists Press, Palo Alto, CA.
- Fanning, J.R., Bell, M.D., Fiszdon, J.M., 2012. Is it possible to have impaired neurocognition but good social cognition in schizophrenia? *Schizophr. Res.* 135 (1–3), 68–71.
- Fett, A.K., Viechtbauer, W., Dominguez, M.D., Penn, D.L., van Os, J., Krabbendam, L., 2011. The relationship between neurocognition and social cognition with functional outcomes in schizophrenia: a meta-analysis. *Neurosci. Biobehav. Rev.* 35 (3), 573–588.
- Fioravanti, M., Bianchi, V., Cinti, M.E., 2012. Cognitive deficits in schizophrenia: an updated metanalysis of the scientific evidence. *BMC Psychiatry* 12, 64.
- Forbes, C.E., Grafman, J., 2010. The role of the human prefrontal cortex in social cognition and moral judgment. *Annu. Rev. Neurosci.* 33, 299–324.
- Frith, C.D., 2008. Social cognition. *Phil. Trans. R. Soc. B: Biol. Sci.* 363 (1499), 2033–2039.
- Fusar-Poli, P., Nelson, B., Valmaggia, L., Yung, A.R., McGuire, P.K., 2014. Comorbid depressive and anxiety disorders in 509 individuals with an at-risk mental state: impact on psychopathology and transition to psychosis. *Schizophr. Bull.* 40 (1), 120–131.
- Galderisi, S., Rossi, A., Rocca, P., Bertolino, A., Mucci, A., Bucci, P., Rucci, P., Gibertoni, D., Aguglia, E., Amore, M., Bellomo, A., Biondi, M., Brugnoli, R., Dell'Oso, L., De Ronchi, D., Di Emidio, G., Di Giannantonio, M., Fagioli, A., Marchesi, C., Monteleone, P., Oldani, L., Pinna, F., Roncone, R., Sacchetti, E., Santonastaso, P., Siracusano, A., Vita, A., Zeppegno, P., Maj, M., Italian Network for Research on Psychoses, 2014. The influence of illness-related variables, personal resources and context-related factors on real-life functioning of people with schizophrenia. *World Psychiatry* 13 (3), 275–287.
- García-Casal, J.A., Goñi-Imizcoz, M., Perea-Bartolomé, M.V., Soto-Pérez, F., Smith, S.J., Calvo-Simal, S., Franco-Martín, M., 2017. The efficacy of emotion recognition rehabilitation for people with Alzheimer's disease. *J. Alzheimer's Dis.* 57 (3), 937–951.
- Gray, H.M., Tickle-Degnen, L., 2010. A meta-analysis of performance on emotion recognition tasks in Parkinson's disease. *Neuropsychology* 24 (2), 176–191.
- Green, M.F., Penn, D.L., Bentall, R., Carpenter, W.T., Gaebel, W., Gur, R.C., Kring, A.M., Park, S., Silverstein, S.M., Heinssen, R., 2008. Social cognition in schizophrenia: an NIMH workshop on definitions, assessment, and research opportunities. *Schizophr. Bull.* 34 (6), 1211–1220.
- Green, M.F., Horan, W.P., Lee, J., 2015. Social cognition in schizophrenia. *Nat. Rev. Neurosci.* 16, 620–631.
- Green, M.F., 2016. Impact of cognitive and social cognitive impairment on functional outcomes in patients with schizophrenia. *J. Clin. Psychiatry* 77 (Suppl. 2), 8–11.
- Gregory, C., Lough, S., Stone, V., Erzincliglu, S., Martin, L., Baron-Cohen, S., Hodges, J.R., 2002. Theory of mind in patients with frontal variant frontotemporal dementia and Alzheimer's disease: theoretical and practical implications. *Brain* 125 (Pt 4), 752–764.
- Happé, F., Frith, U., 1996. The neuropsychology of autism. *Brain* 119 (Pt 4), 1377–1400.
- Henry, J.D., Cowan, D.G., Lee, T., Sachdev, P.S., 2015. Recent trends in testing social cognition. *Curr. Opin. Psychiatry* 28 (2), 133–140.
- Henry, J.D., von Hippel, W., Molenberghs, P., Lee, T., Sachdev, P.S., 2016. Clinical assessment of social cognitive function in neurological disorders. *Nat. Rev. Neurol.* 12 (1), 28–39.
- Higgins, J.P.T., Green, S. (Eds.), 2011. *Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0* [updated March 2011]. The Cochrane Collaboration Available from: [www.handbook.cochrane.org](http://www.handbook.cochrane.org).
- Hutchinson, A.D., Mathias, J.L., 2007. Neuropsychological deficits in frontotemporal dementia and Alzheimer's disease: a meta-analytic review. *J. Neurol. Neurosurg. Psychiatry* 78 (9), 917–928.
- Iacoviello, B.M., Wu, G., Alvarez, E., Huryk, K., Collins, K.A., Murrough, J.W., Iosifescu, D.V., Charney, D.S., 2014. Cognitive-emotional training as an intervention for major depressive disorder. *Depress. Anxiety* 31 (8), 699–706.
- Kohler, C.G., Walker, J.B., Martin, E.A., Healey, K.M., Moberg, P.J., 2010. Facial emotion perception in schizophrenia: a meta-analytic review. *Schizophr. Bull.* 36 (5), 1009–1019.
- Kohler, C.G., Hoffman, L.J., Eastman, L.B., Healey, K., Moberg, P.J., 2011. Facial emotion perception in depression and bipolar disorder: a quantitative review. *Psychiatry Res.* 188 (3), 303–309.
- Kurtz, M.M., Gagen, E., Rocha, N.B., Machado, S., Penn, D.L., 2016. Comprehensive treatments for social cognitive deficits in schizophrenia: a critical review and effect-size analysis of controlled studies. *Clin. Psychol. Rev.* 43, 80–89.
- Lagravinese, G., Avanzino, L., Raffo De Ferrari, A., Marchese, R., Serrati, C., Mandich, P., Abbruzzese, G., Pelosin, E., 2017. Theory of mind is impaired in mild to moderate Huntington's Disease independently from global cognitive functioning. *Front. Psychol.* 8, 80.
- Lakens, D., 2013. Calculating and reporting effect sizes to facilitate cumulative science: a practical primer for t-tests and ANOVAs. *Front. Psychol.* 4, 863.
- Lavin, C., Melis, C., Mikulan, E., Gelormini, C., Huepe, D., Ibañez, A., 2013. The anterior cingulate cortex: an integrative hub for human socially-driven interactions. *Front. Neurosci.* 7, 64.
- Leppanen, J., Ng, K.W., Tchanturia, K., Treasure, J., 2017. Meta-analysis of the effects of intranasal oxytocin on interpretation and expression of emotions. *Neurosci. Biobehav. Rev.* 78, 125–144.
- Lindquist, K.A., Wager, T.D., Kober, H., Bliss-Moreau, E., Barrett, L.F., 2012. The brain basis of emotion: a meta-analytic review. *Behav. Brain Sci.* 35 (3), 121–143.
- Mehta, U.M., Thirhalli, J., Subbakrishna, D.K., Gangadhar, B.N., Eack, S.M., Keshavan, M.S., 2013. Social and neuro-cognition as distinct cognitive factors in schizophrenia: a systematic review. *Schizophr. Res.* 148 (1–3), 3–11.
- Mercedes Perez-Rodriguez, M., Mahon, K., Russo, M., Ungar, A.K., Burdick, K.E., 2015. Oxytocin and social cognition in affective and psychotic disorders. *Eur. Neuropsychopharmacol.* 25 (2), 265–282.
- Meyer-Lindenberg, A., Domes, G., Kirsch, P., Heinrichs, M., 2011. Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine. *Nat. Rev. Neurosci.* 12 (9), 524–538.
- Mitchell, R.L., Phillips, L.H., 2015. The overlapping relationship between emotion perception and theory of mind. *Neuropsychologia* 70, 1–10.
- Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., PRISMA Group, 2009. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *BMJ* 339, b2535.
- Molenberghs, P., Johnson, H., Henry, J.D., Mattingley, J.B., 2016. Understanding the minds of others: a neuroimaging meta-analysis. *Neurosci. Biobehav. Rev.* 65, 276–291.
- Nilsson, K.K., de López, K.J., 2016. Theory of mind in children with specific language impairment: a systematic review and meta-analysis. *Child Dev.* 87 (1), 143–153.
- Patriquin, M.A., DeRamus, T., Libero, L.E., Laird, A., Kana, R.K., 2016. Neuroanatomical and neurofunctional markers of social cognition in autism spectrum disorder. *Hum. Brain Map.* 37 (11), 3957–3978.
- Penton-Voak, I.S., Bate, H., Lewis, G., Munafò, M.R., 2012. Effects of emotion perception training on mood in undergraduate students: randomised controlled trial. *Br. J. Psychiatry* 201 (1), 71–72.
- Penton-Voak, I., Munafò, M., Looi, C.Y., 2017. Biased facial emotion perception in mental health disorders: a possible target for psychological intervention? *Curr. Dir. Psychol. Sci.* 26 (3), 294–301.
- Phillips, L.H., Henry, J.D., Scott, C., Summers, F., Whyte, M., Cook, M., 2011. Specific impairments of emotion perception in multiple sclerosis. *Neuropsychology* 25 (1), 131–136.
- Pinkham, A.E., Penn, D.L., Green, M.F., Harvey, P.D., 2016. Social cognition psychometric evaluation: results of the initial psychometric study. *Schizophr. Bull.* 42 (2), 494–504.
- Plana, I., Lavoie, M.A., Battaglia, M., Achim, A.M., 2014. A meta-analysis and scoping review of social cognition performance in social phobia, posttraumatic stress disorder and other anxiety disorders. *J. Anxiety Disord.* 28 (2), 169–177.
- Poletti, M., Enrici, I., Adenzato, M., 2012. Cognitive and affective Theory of Mind in neurodegenerative diseases: neuropsychological, neuroanatomical and neurochemical levels. *Neurosci. Biobehav. Rev.* 36 (9), 2147–2164.
- Prakash, R.S., Snook, E.M., Lewis, J.M., Motl, R.W., Kramer, A.F., 2008. Cognitive impairments in relapsing-remitting multiple sclerosis: a meta-analysis. *Mult. Scler.* 14 (9), 1250–1261.
- Preti, A., Melis, M., Siddi, S., Vellante, M., Doneddu, G., Fadda, R., 2014. Oxytocin and autism: a systematic review of randomized controlled trials. *J. Child Adolesc. Psychopharmacol.* 24 (2), 54–68.
- Richman, M.J., Unoka, Z., 2015. Mental state decoding impairment in major depression and borderline personality disorder: meta-analysis. *Br. J. Psychiatry* 207 (6), 483–489.
- Savla, G.N., Vella, L., Armstrong, C.C., Penn, D.L., Twamley, E.W., 2013. Deficits in domains of social cognition in schizophrenia: a meta-analysis of the empirical evidence. *Schizophr. Bull.* 39 (5), 979–992.
- Seeley, W.W., Crawford, R.K., Zhou, J., Miller, B.L., Greicius, M.D., 2009. Neurodegenerative diseases target large-scale human brain networks. *Neuron* 62 (1), 42–52.
- Siegt, R.J., Abernethy, D.A., 2005. Depression in multiple sclerosis: a review. *Journal of Neurology. Neurosurg. Psychiatry* 76 (4), 469–475.
- Stewart, E., Catroppa, C., Lah, S., 2016. Theory of mind in patients with epilepsy: a systematic review and meta-analysis. *Neuropsychol. Rev.* 26 (1), 3–24.
- Trevisan, D.A., Birmingham, E., 2016. Are emotion recognition abilities related to everyday social functioning in ASD? A meta-analysis. *Res. Autism Spectr. Disord.* 32, 24–42.
- Ulfvebrand, S., Birgegård, A., Norring, C., Högdahl, L., von Hausswolff-Juhlin, Y., 2015. Psychiatric comorbidity in women and men with eating disorders results from a large clinical database. *Psychiatry Res.* 230 (2), 294–299.
- van Donkersgoed, R.J., Wunderink, L., Nieboer, R., Aleman, A., Pijnenborg, G.H., 2015. Social cognition in individuals at ultra-high risk for psychosis: a meta-analysis. *PLoS One* 10 (10), e0141075.
- Van Overwalle, F., 2009. Social cognition and the brain: a meta-analysis. *Hum. Brain Map.* 30 (3), 829–858.
- Vaskinn, A., Sundet, K., Østefjells, T., Nymo, K., Melle, I., Ueland, T., 2016. Reading emotions from body movement: a generalized impairment in schizophrenia. *Front. Psychol.* 6, 2058.
- Yirmiya, N., Erel, O., Shaked, M., Solomonica-Levi, D., 1998. Meta-analyses comparing theory of mind abilities of individuals with autism, individuals with mental retardation, and normally developing individuals. *Psychol. Bull.* 124 (3), 283–307.